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ABSTRACT 39 
Aim: Gut microbial dysbiosis is implicated in the pathogenesis of non-alcoholic 40 
steatohepatitis (NASH). We investigated downstream effects of gut microbiota modulation 41 
on markers of hepatic inflammation, steatosis, and hepatic and peripheral insulin sensitivity 42 
in patients with NASH using Rifaximin therapy. 43 
Methods: Patients with biopsy-proven NASH and elevated aminotransferase values were 44 
included in this open-label pilot study, all receiving 6 weeks Rifaximin 400mg twice daily, 45 
followed by a 6 week observation period. The primary endpoint was change in ALT after 6 46 
weeks of Rifaximin. Secondary endpoints were change in hepatic lipid content and insulin 47 
sensitivity measured with a hyperinsulinaemic euglycaemic clamp. 48 
Results: Fifteen patients, 13 male, 2 female, with median (range) age 46(32-63) years were 49 
included. Seven had diabetes on oral hypoglycaemic medications and 8 had no diabetes. 50 
After 6 weeks of therapy, no differences were seen in ALT (55 [33-191] versus 63 [41-51 
218]IU/L, p=0.41), peripheral glucose uptake (28.9 [19.4-48.3] to 25.5 [17.7-47.9] 52 
µmol/kg/min, p=0.30), hepatic insulin sensitivity (35.2 [15.3-51.7]% versus 30.0 [10.8-53 
50.5]%, p=0.47), or hepatic lipid content (21.6[2.2-46.2]% before and 24.8[1.7-59.3]% after 54 
Rifaximin, p=0.59) before and after Rifaximin treatment.  After 12 weeks from baseline, 55 
serum ALT increased to 83(30-217)IU/L, p=0.02. There was a significant increase in HOMA-IR 56 
(p=0.05). The urinary metabolic profile indicated a significant reduction in urinary hippurate 57 
with treatment, which reverted to baseline after cessation of Rifaximin, although there was 58 
no consistent difference in relative abundance of faecal microbiota with treatment.  59 
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Conclusion: These data do not indicate a beneficial effect of Rifaximin in patients with 60 
NASH.  61 
Abstract 248 words (max 250) 62 
 63 
Key words: 64 
Antibiotic; Hippurate; Insulin resistance; Microbiota; NAFLD; Non-alcoholic steatohepatitis 65 
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INTRODUCTION 68 
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver dysfunction and 69 
an increasing cause of liver-related morbidity and mortality globally(1, 2). NAFLD, and its 70 
inflammatory and potentially progressive subtype, non-alcoholic steatohepatitis (NASH), 71 
represents a complex disease trait, with genetic and environmental influences on incidence 72 
and disease progression(2, 3). While lifestyle measures in order to achieve sustained weight 73 
loss, including dietary changes and regular exercise are the mainstay of current 74 
management(4), many patients do not respond to such measures and specific therapies are 75 
lacking(5, 6). 76 
 77 
The gut microbiota is increasingly recognised as a key metabolic influence in the body and a 78 
potentially modifiable environmental target in disorders of energy metabolism and fat 79 
storage(7).  Mechanisms include increase of calorific yield of meals by co-digestion, 80 
production of short chain fatty acids and bacterial endotoxin (7, 8)(9).  81 
 82 
Microbial interventions, such as transfer of caecal contents from conventionally-raised mice 83 
to germ free mice have been shown to alter the host phenotype(7), while a study in patients 84 
with the metabolic syndrome demonstrated improved insulin sensitivity in patients 85 
receiving a faecal allogenic enteric infusion from a lean donor than from an autologous 86 
infusion(10). Besides direct microbial transfer, other methods for alteration of the gut 87 
microbiota include use of prebiotics, probiotics and antibiotics(11). Antibiotic therapy in 88 
obese mice reduced LPS and improved the metabolic phenotype(12), while Rifaximin was 89 
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found to reduce endotoxinaemia in patients with decompensated cirrhosis, associated with 90 
improvements in hepatic synthetic function, but not aminotransferase values(13). 91 
 92 
Rifaximin is a minimally-absorbed, broad spectrum antibiotic, which has been found to have 93 
clinical utility in a number of gastrointestinal settings with few side effects(14-16). With 94 
standard oral dosing, intraluminal drug levels exceed the minimum inhibitory 95 
concentrations for most bacterial species by up to 250-fold, while systemic absorption is 96 
<0.4% of the dose(17).  97 
 98 
We hypothesised that modulation of the gut microbiota, using Rifaximin, in humans with 99 
NASH would lead to improvement in hepatic inflammation, hepatic lipid content and insulin 100 
sensitivity. Thus, we conducted a pilot prospective clinical trial to evaluate the efficacy and 101 
safety of such an approach. We examined the faecal microbiota, urinary metabolome and 102 
inflammatory cytokine profile as secondary analyses to assess whether any changes 103 
observed were linked to detectable differences in bacterial populations, to microbial co-104 
metabolism and whether this could be mediated by inflammatory signalling. 105 
 106 
METHODS 107 
Ethical approval (REC 10/H0711/58) was obtained and the study was registered on the 108 
European Clinical Trials Database (EudraCT 2010-021515-17). Patients were recruited from 109 
Hepatology clinics at a single UK centre (Imperial College Healthcare NHS Trust) between 110 
May 2011 and June 2012. Informed consent was obtained from all patients included in the 111 
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study and the study protocol conforms to the ethical guidelines of the 1975 Declaration of 112 
Helsinki as reflected in a priori approval by the institution's human research and ethics 113 
committee (West London REC 2). Male and female patients were eligible for inclusion if 114 
aged between 18 and 70 years with non-alcoholic steatohepatitis histologically-proven, as 115 
evidenced by the presence of all of: steatosis, hepatocyte ballooning and lobular 116 
inflammation, and scored according to Kleiner(18) by a single experienced histopathologist 117 
(RDG) within the previous year, with or without mild to moderate fibrosis (stage 0-3/4) and 118 
with persistently elevated alanine aminotransferase (ALT) values on at least two occasions 119 
in the three months prior to recruitment. Patients were excluded if there was histological 120 
evidence of cirrhosis; hepatic decompensation; regular alcohol consumption exceeding 14 121 
units/week (16g ethanol/day) for a woman or 21 units/week (24g ethanol/day) for a man; 122 
evidence of viral, autoimmune or other metabolic liver disease on a chronic liver disease 123 
screen; a history of malignancy or systemic inflammatory conditions; myocardial infarction 124 
or cerebrovascular events in the preceding 6 months; a history of bariatric surgery, blind 125 
loop or short bowel; use of any treatment known or suspected to change bowel flora within 126 
3 months of enrolment; initiation or major dose change of metformin, thiazolinediones, 127 
biguanides, statins, fibrates, anti-obesity medications or insulin within 3 months of 128 
enrolment. 129 
 130 
Study design 131 
This was an open-label study of Rifaximin (Normix, Alfa Wasserman S.p.A, Bologna, Italy) 132 
400mg twice daily for six weeks followed by a further six weeks observation period during 133 
which patients received standard care. Compliance with treatment was checked by 134 
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collection of empty blister packs. Subjects were asked to provide a structured dietary and 135 
lifestyle history as previously described(19). The primary endpoint was change in ALT after 6 136 
weeks’ RifaǆiŵiŶ therapǇ. SeĐoŶdarǇ eŶdpoiŶts were ĐhaŶge iŶ hepatiĐ aŶd whole-body 137 
insulin sensitivity assessed by the two-stage hyperinsulinaemic euglycaemic clamp and 138 
change in hepatic triglyceride content assessed by proton nuclear magnetic resonance 139 
spectroscopy at 6 weeks from baseline. Serum ALT, biochemistry and anthropometrics were 140 
also measured at 12 weeks to look for longer-term effects. Stool microbiota, urinary 141 
metabolic profile and serum cytokine profile were measured before and after intervention.  142 
Laboratory measurement 143 
Routine biochemistry was undertaken by the hospital biochemistry laboratory on the 144 
Aeroset (ALT, AST, HDL, triglyceride) or Architect (insulin) clinical chemistry analyser 145 
platforms (Abbott Diagnostics, Illinois, USA). Insulin concentrations were determined using a 146 
one-step chemiluminescent immunoassay. Cytokine analysis was performed by Aushon 147 
Multiplex Immunoassay Analysis (Aushon Biosystems, Billerica, USA). 148 
Hyperinsulinaemic euglycaemic clamp 149 
The two-step hyperinsulinaemic euglycaemic clamp combined with a [6,6-2H2]glucose 150 
infusion to measure insulin sensitivity was performed as previously described and detailed 151 
in the supplementary information (20). Patients consumed nothing but water orally after 152 
eating a low-fat pre-prepared meal (identical before and after intervention) 10 hours prior 153 
to the clamp study.  154 
Plasma glucose concentration and enrichment time-courses were smoothed using optimal 155 
segments analysis(21) and non-steady-state equations(22) 156 
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 157 
Proton nuclear magnetic resonance spectroscopy 158 
Patients fasted for at least 10 hours prior to scanning.  Rapid T1-weighted magnetic 159 
resonance images were acquired using a 1.5T Phillips AchievaTM scanner (Philips Medical 160 
Systems, Best, Netherlands), as previously described(23). Proton nuclear magnetic 161 
resonance (1H NMR) spectra were acquired at 1.5T, using a surface coil. Transverse images 162 
of the liver were used to ensure accurate positioning of the (20x20x20 mm) voxel in the 163 
liver, avoiding blood vessels, the gall bladder and fatty tissue. Spectra were obtained from 164 
the right lobe of the liver using a PRESS sequence (TR 1500ms, TE 135 ms) without water 165 
saturation and with 128 signal averages. Intrahepatocellular lipids (IHCL) were measured 166 
relative to liver water content, as previously described(24).  167 
Faecal microbiota 168 
Faeces were collected in a sterile container at each assessment visit and frozen at -ϳ0⁰C 169 
within 10 minutes. DNA was extracted using a Qiagen DNA stool extraction kit (Qiagen, 170 
Manchester, UK), with an additional bead beating step added before the ASL buffer was 171 
added to the stool sample. The extracted DNA was quantified using a Qubit platform and all 172 
DNA samples were normalised to 10 ng/µL. The 16S rRNA gene was amplified using primers 173 
for the V1 to V3 regions and sequenced using paired end 250bp chemistry on an Illumina 174 
MiSeq platform (Illumina Inc, San Diego, California). The data were analysed using 175 
bioinformatics statistical packages (Mothur, STAMP) and R (R Foundation, Vienna, Austria) 176 
to determine whether any statistically significant changes in the profiles of the faecal 177 
microbiota had occurred(25-27). 178 
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 179 
Urinary metabolomics 180 
Urine was collected, processed and buffered as detailed in the supplementary information. 181 
All NMR spectra were referenced, phased and baselined corrected as detailed in the 182 
supplementary information. Data were initially modelled using unsupervised principle 183 
components analysis (PCA) and subsequently combined with clinical data and modelled 184 
using orthogonal partial least squares discriminant analysis (OPLS-DA). For univariate 185 
analyses Topspin (Bruker, Billerica, USA) was used to integrate under spectral resonances 186 
for metabolites of interest and the quantitative data was analysed in the statistics package 187 
SPSS (IBM, Armonk, USA). 188 
Statistical analysis 189 
Statistical analyses were performed using SPSS 20.0 (SPSS Inc., Chicago, USA). Based on 190 
historical data from 20 patients with paired ALT data in response to lifestyle and standard of 191 
care intervention from the NAFLD clinic at our institution, a sample size of 16 would provide 192 
80% power and  of 0.05 to detect a change in ALT of 25IU/L with an expected standard 193 
deviation of the difference of 33IU/L. Data were non-parametrically distributed, so are 194 
displayed as median (range). Significance of differences in endpoints before and after 195 
intervention was tested by the Wilcoxon Signed Rank test.  196 
 197 
RESULTS 198 
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Of the 77 patients with biopsy-proven NAFLD evaluated in clinic over the recruitment 199 
period, 41 met inclusion criteria and were invited to take part in the study. On receipt of the 200 
patient information, 18 patients declined to participate and 23 were screened. Of these, a 201 
further two declined to participate further at the screening visit and three were excluded by 202 
the screening questionnaire. Of the 15 patients who initiated the study protocol, one 203 
participant was unable to tolerate MR scanning owing to claustrophobia and another 204 
participant declined the hyperinsulinaemic euglycaemic clamp having already started the 205 
study.  Baseline patient characteristics are displayed in Table 1. 100% compliance with 206 
Rifaximin therapy was reported by all participants. One subject noted loose stools for 36 207 
hours during therapy, which resolved spontaneously and therapy was not discontinued. No 208 
other adverse events were recorded. Recruitment was halted after enrolment of 15 subjects 209 
because of difficulty in recruitment to the full study protocol over the defined study time 210 
period. 211 
Hepatocellular inflammation 212 
Alanine aminotransferase (ALT) values, the primary endpoint in this study, were 55IU/L (33-213 
191) before Rifaximin, 63IU/L (41-218) after ϲ weeks’ Rifaximin (p=0.41 compared to 214 
baseline) and 83IU/L (30-217) after a further 6 weeks follow-up (p=0.017 compared to 215 
baseline), Figure 1A. Anthropometrics, HOMA-IR and lipid profile before and after Rifaximin 216 
are shown in Table 2. There was a significant increase in HDL and HOMA-IR at 12 weeks. 217 
Hepatic Lipid content 218 
Hepatic lipid content (IHCL) was 21.6% (2.2-46.2) before and 24.8% (1.7-59.3) after 219 
Rifaximin, p=0.59. Figure 1B.  220 
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Insulin sensitivity 221 
Hepatic insulin sensitivity as assessed by suppression of hepatic glucose production was 222 
35.2% (15.3-51.7) before Rifaximin and 30.0% (10.8-50.5) after Rifaximin, p=0.47, Figure 1C. 223 
Peripheral insulin sensitivity as assessed by glucose Rd was 28.9 mol/kg/min (19.4-48.3) 224 
before Rifaximin and 25.5 mol/kg/min (17.7-47.9) after Rifaximin, p=0.30, Figure 1D.  225 
Cytokine analysis 226 
There were no differences in serum cytokine values, including TNF and IL-1 before and 227 
after treatment with Rifaximin, and over the observation periods (Supplementary Table 1). 228 
 229 
Urinary metabonomics 230 
Urinary metabolites were identified as seen in the representative urinary metabolic profile, 231 
Figure 2A. Principal components analysis of urinary metabolic profiles demonstrated close 232 
clustering of quality control samples and case samples clustered by patient, Figure 2B. 233 
Supervised partial least squares discriminant analysis (OPLS-DA) failed to produce robust, 234 
predictive models based upon the effect of treatment upon urinary metabolic profiles. 235 
Examination of the loadings plots for the OPLS-DA models identified three metabolites, 236 
alanine, creatinine and hippurate, with modest correlation with treatment status, Figure 2C. 237 
These metabolites were examined further in univariate analyses, Figure 2D. A significant 238 
decrease in hippurate levels was observed following treatment with rifaximin (p=0.048). A 239 
significant increase in hippurate levels was seen from immediately after treatment to 6 240 
weeks after its discontinuation (p=0.035); no difference was seen between 6 weeks post-241 
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treatment and pre-treatment hippurate levels (p=0.721). There were no statistically 242 
significant changes in alanine or creatinine levels with treatment. 243 
 244 
Stool Microbiota 245 
No consistent differences were observed in the relative abundance of gut microbiota at the 246 
phylum level in faeces with Rifaximin treatment (Figure 3). However significant differences 247 
in the microbiota were seen at the genus level in individual patients with Rifaximin 248 
treatment (Supplementary Figure 1, published online), although these differences were not 249 
common to all subjects. 250 
 251 
DISCUSSION 252 
In this study, we performed an open-label clinical trial of Rifaximin in patients with NASH to 253 
test effect and safety. Although there was no evidence of change in markers of hepatic 254 
inflammation, hepatic lipid content or insulin sensitivity after 6 weeks of therapy, serum ALT 255 
values increased significantly from baseline to 12 weeks, in association with increased 256 
insulin resistance as assessed by the HOMA-IR score. An increase in serum HDL values was 257 
also observed. Univariate analysis of urinary hippurate levels suggests that treatment 258 
transiently suppressed the production of this metabolite. However, robust changes were 259 
not demonstrated in the faecal microbiota, or a panel of pro- and anti-inflammatory serum 260 
cytokines. No adverse events were recorded. These results contrast with another recent 261 
open label study of Rifaximin in NAFLD/NASH which reported an improvement in liver 262 
biochemistry, body mass index and IL-10 after 28 days of Rifaximin 1200mg per day in 27 263 
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patients with NASH, although insulin sensitivity, liver fat and gut microbiota were not 264 
assessed specifically in that study(28). 265 
 266 
Ours was a prospective clinical study in which subjects were intensively investigated to look 267 
for signals of biological effect of Rifaximin on NASH in human subjects that might form the 268 
basis of larger studies of longer duration. The sample size is relatively small, but the study 269 
was powered to detect a difference in ALT of 25IU/L with treatment, which was not seen. 270 
This study included more patients than studies using the hyperinsulinaemic euglycaemic 271 
clamp to assess the effects of antibiotic administration and faecal transfer on insulin 272 
sensitivity(10, 29), so might be expected to show a difference in insulin sensitivity if 273 
Rifaximin were to cause an effect of similar magnitude to those interventions. The study was 274 
of similar size to studies assessing the microbial and metabolic effects of Rifaximin in 275 
cirrhosis(30, 31) and the effect of Rifaximin on liver biochemistry in patients with PSC(32). 276 
Nevertheless, the study was not powered to detect differences in subgroups, such as those 277 
with and without type 2 diabetes mellitus. The six-week course of therapy may be 278 
considered short, but metabolic effects of antibiotics are seen at 1 week(29) and changes in 279 
hepatocellular inflammation are detectable rapidly in serum. The dose of Rifaximin used in 280 
this study is lower than in other recent clinical trials which have used 550mg twice daily, a 281 
dose licenced for use in the secondary prophylaxis of hepatic encephalopathy(14). This 282 
difference reflects the Rifaximin preparations and dosing information available, and the 283 
clinical usage for gastrointestinal infections at the time of study initiation. Assessment of 284 
changes to the intestinal microbiota using sequencing of faecal bacterial DNA is limited as 285 
the faecal microbiota may not reflect the metabolically active microbiota at the small bowel 286 
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mucosa, which are implicated in the effects of Rifaximin and more readily sampled in animal 287 
studies(33).  288 
 289 
Although the primary and secondary outcome measures were not altered by Rifaximin in 290 
this study, some additional markers changed post-treatment. These differences were not 291 
specified in the a priori analysis so should be interpreted tentatively at this stage. However, 292 
this, and other studies, suggest that some broad spectrum oral antibiotics, including 293 
Rifaximin, may be associated with adverse metabolic and hepatic responses. For example, 294 
oral administration of a short course of vancomycin reduced peripheral insulin sensitivity in 295 
patients with the metabolic syndrome, in association with reduced gut microbial 296 
diversity(29). In another study of  patients with cirrhosis before and after Rifaximin 297 
administration, there was a reduction in the ratio of secondary to primary bile acids(31), 298 
suggesting a possible mechanism for any Rifaximin-induced insulin resistance. As in the 299 
present study, previous work using a systems biology approach to evaluate metabolic and 300 
microbial effects of Rifaximin in patients with cirrhosis and minimal hepatic encephalopathy 301 
demonstrated no significant difference in the overall microbiome composition of stool(30). 302 
So, in contrast with in vitro studies, which demonstrate activity against a broad-spectrum of 303 
bacteria(34), the effects of Rifaximin in vivo may be on bacterial function and virulence, 304 
rather than simply a reduction in numbers(35, 36). The observation in the present study that 305 
urinary hippurate levels decreased with Rifaximin therapy is relevant as urinary hippurate is 306 
influenced by the intestinal microbiota (as well as age, sex and dietary intake, which were 307 
controlled for in the present study)(37). Hippurate is a glycine conjugate of benzoic acid and 308 
a normal constituent of the human urinary metabolite profile. Germ-free mice have 309 
significantly lower levels of urinary hippurate than conventially raised mice(38) and 310 
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administration of vancomycin to mice leads to changes in the faecal microbiome and 311 
associated suppression of urinary hippurate levels(39). Metabolism of high-molecular 312 
weight polyphenolic compounds by colonic microbiota leads to production of benzoic acid 313 
which may be excreted as hippurate(37). Differential capacities of microbiota species to 314 
metabolise polyphenolic compounds(40) means that antibiotic-mediated changes in 315 
bacterial numbers or population composition may alter the bioavailability of upstream 316 
metabolites of benozoic acid and this lead to changes in urinary hippurate levels. Benzoic 317 
acid is converted to hippurate predominantly in hepatic mitochondria and impaired hepatic 318 
function is associated with a decreased capacity to produce hippurate from orally or 319 
intravenously administered precursors(41, 42). Thus there is some evidence that the 320 
transient depression in urinary hippurate levels with Rifaximin in this study is mediated by 321 
suppression of such activity by colonic microbiota. 322 
This work indicates that the use of a minimally-absorbed, broad spectrum antibiotic is not 323 
associated with consistent changes in the stool microbiota at the phylum or genus level, but 324 
suggests a metabolic effect, illustrated by the urinary hippurate levels. Nevertheless, such 325 
an intervention has not led to detectable changes in ALT, insulin sensitivity and hepatic 326 
steatosis, nor is it associated with a robust pattern of inflammatory cytokines. This study 327 
does not support the use of antibiotics as a therapeutic intervention in NASH, but suggests a 328 
possible adverse metabolic effect which needs further evaluation. The variable effect of this 329 
intervention at a genus level between patients indicates that future studies should focus on 330 
functional niches rather than the abundance of the microbiota to direct therapy. Future 331 
therapies targeting the gut microbiota will need to be more nuanced to result in beneficial 332 
metabolic and inflammatory modulation. 333 
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Administration of Rifaximin for 6 weeks to subjects with non-alcoholic steatohepatitis was 334 
not associated with changes in markers of hepatocellular damage, hepatic triglyceride 335 
content, insulin sensitivity or systemic inflammation at 6 weeks, although an increase in 336 
serum ALT levels was noted at 12 weeks, associated with increased HOMA-IR and HDL. On 337 
the basis of the evidence presented in this study, Rifaximin cannot be recommended as a 338 
potential therapy in NAFLD/NASH, but further studies are warranted to investigate the 339 
hepatic and metabolic consequences of enteric antibiotic therapies.  340 
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Table 1. Baseline Characteristics.  471 
Characteristic Total cohort 
Number 15 
Gender, M/F 13/2 
Age, yrs 46 (32-63) 
Weight, kg 83.8 (66.3-116.0) 
BMI, kg/m2 27.2 (22.9-35.3) 
Waist, cm 101.9 (86.9-127.3) 
Diabetes, Y/N 7/8 
AďdoŵiŶal OďesitǇΏ, Y/N 14/1 
DyslipidaemiaΏ , Y/N 11/4 
HypertensionΏ, Y/N 9/6 
Metabolic syndromeΏ, Y/N 9/6 
ALT, IU/L 55 (33-191) 
AST, IU/L 35 (20-100) 
Triglyceride, mmol/L 1.69 (0.94-2.94) 
HDL, mmol/L 1.07 (0.73-1.45) 
HOMA -IR 3.65 (1.52- 8.18) 
Histologyΐ  
Steatosis, 0/1/2/3 0/4/8/3 
Ballooning, 0/1/2/3 0/12/3/0 
Lobular inflammation, 0/1/2 0/12/3 
Fibrosis, 0/1/2/3/4 1/6/4/4/0 
Data expressed as numbers or median (range) as appropriate. ΏIDF criteria 2005. ΐ Kleiner 472 
et al. 2005 473 
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 474 
Table 2. Anthropometrics and metabolic clinical chemistry 475 
 Pre-Rifaximin (0 
weeks) 
Post-Rifaximin (6 
weeks) 
ΏP= Post-Rifaximin (12 
weeks) 
ΏP= 
BMI, kg/m2 27.15 (22.86-35.27) 27.84 (22.92-
35.59) 
0.14 28.08 (22.73-
35.59) 
0.47 
Waist, cm 101.9 (86.9- 127.3) 100.6 (87.7-125.5) 0.58 101.5 (87.0-126.0) 0.27 
HOMA-IR 3.65 (1.52-8.18) 4.31 (1.25-8.54) 0.08 4.29 (2.04-15.71) 0.05 
Total 
Cholesterol, 
mmol/L 
4.68 (2.52-5.98) 4.65 (2.58-7.37) 0.14 4.44 (2.75-7.10) 0.33 
HDL, mmol/L 1.07 (0.73-1.45) 1.11 (0.80-1.45) 0.18 1.19 (0.77-1.62) 0.004 
Triglycerides, 
mmol/L 
1.69 (0.94-2.94) 1.47 (0.81-3.17) 0.73 1.47 (0.76-5.23) 0.89 
Ώcompared to baseline 476 
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FIGURE LEGENDS 478 
 479 
Fig. 1. Primary and secondary study endpoints before and after Rifaximin therapy. (A) 480 
Serum ALT values at baseline, 6 weeks (end of treatment) and 12 weeks (6 weeks after end 481 
of treatment). Individual patient data (n=15). * P=0.41 vs baseline, # P=0.02 vs baseline, 482 
P=0.04 vs 6 wks. (B) Intrahepatocellular lipid content (IHCL), expressed as a percentage, 483 
before and after Rifaximin therapy. Individual patient data (N=14). (C) Hepatic insulin 484 
sensitivity (% suppression of endogenous glucose production, SEGP) before and after 485 
Rifaximin therapy. Individual patient data, (N=14). (D) Peripheral insulin sensitivity (Rd) 486 
before and after Rifaximin therapy. Individual patient data (N=14). 487 
488 
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 489 
Fig. 2. Urinary metabonomic analysis. (A) Typical 1D-NOSEY NMR spectrum of urine. (B) 490 
Scores plot from unsupervised principal components analysis, coloured by timepoint and 491 
labelled by patient identification number. (C) S-line loadings plot from OPLS-DA for pre- and 492 
post- treatment timepoints. (D) Boxplots of quantified metabolites of interest at each study 493 
timepoint. 494 
495 
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 496 
Fig. 3. Effect of Rifaximin on the phylum level composition of faeces. The heatmap shows 497 
the abundance of the phylum-level 16S rRNA gene sequences for each patient pre and post 498 
Rifaximin. Relative abundances of the sequence reads plotted are colour coded from less 499 
(blue) to more abundant (red). The colour value shows log10 fold changes. 500 
 501 
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METHODS 518 
Hyperinsulinaemic euglycaemic clamp 519 
Patients consumed nothing but water orally after eating a low-fat pre-prepared meal 520 
(identical before and after intervention) 10 hours prior to the clamp study. Upon 521 
arrival intravenous cannulae were inserted into both antecubital fossae for blood 522 
sampling and infusion of the glucose isotope, insulin and glucose. A primed infusion 523 
of [6,6-2H2] glucose (170 mg; 1.7 mg.min-1) was administered for 7 hours. Samples 524 
were taken from 100-120 min to measure baseline hepatic glucose production 525 
(HGP). A 2-step hyperinsulinaemic–euglycaemic clamp was commenced at 120 min: 526 
insulin infusion at 0.3 mU.kg-1.min-1 (low-dose) for 120 min to measure the insulin 527 
sensitivity of HGP, then at 1.5 mU.kg-1.min-1 (high-dose) for 180 min to measure 528 
insulin sensitivity of peripheral glucose uptake (Rd). Euglycaemia was maintained by 529 
adjusting a 20% glucose infusion, spiked with [6,6-2H2] glucose (7 mg.g-1 glucose for 530 
low-dose, 10 mg.g-1 high dose) according to 5 minute plasma glucose measurements 531 
to keep the patient’s blood glucose level at a target concentration of 5 ± 0.5 mmol/L.  532 
Plasma glucose concentration and enrichment time-courses were smoothed using 533 
optimal segments analysis(1). HGP and Rd (µmol.kg-1.min-1) were calculated using 534 
non-steady-state equations(2), assuming a volume of distribution of 22% body 535 
weight. Hepatic insulin sensitivity was calculated as (basal HGP (90-120 min) – HGP 536 
during low-dose insulin (210-240 min)/basal HGP) x 100. Glucose Rd was calculated 537 
at steady-state following high-dose insulin (390-420 min)  538 
 539 
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Urinary metabolomics 541 
Urine was collected in a sterile container at each assessment visit, centrifuged to 542 
remove sediment and frozen at -70⁰C within 30 minutes.  For analysis, 540l of urine 543 
was centrifuged at 14,000 rpm for 15 minutes and buffered with 60l NMR buffer 544 
(containing TSP), then plated into 96-rack NMR plate. Control samples comprising 545 
an equal mixture of all case samples were generated and prepared in the same 546 
manner. An NPC NMR machine (Bruker, Billerica, USA) with a refrigerated robotic 547 
sample-handling unit was used. Two NMR experiments (NOSEY and J-resolved) 548 
were conducted on each sample. All spectra were referenced to trimethylsilyl 549 
propionic acid (TSP) and a sharp and appropriately sited water peak. A Bruker 550 
automated script was used to perform Fourier transforming, phasing and baselining. 551 
Resulting spectra were aligned and subsequently trimmed and the water peak 552 
removed prior to normalisation using in-house Matlab scripts (Mathworks, Natick, 553 
USA). Resulting spectral data were imported into Simca (Umetrics, San Jose, USA).  554 
 555 
 556 
 557 
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 559 
 560 
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Supplementary Table 1. Serum Cytokine and Adipokine values before and after 563 
Rifaximin  564 
Cytokine Pre-Rifaximin Post-Rifaximin P 
IL1beta*, pg/mL 0.55 (0.01-3.41) 0.57 (0.12-3.07) 1.00 
IL6, pg/mL 4.52 (1.65-43.32) 3.09 (1.50-56.23) 0.39 
IL10, pg/mL 0.76 (0.18-5.64) 0.95 (0.12-6.31) 0.96 
IL18, pg/mL 318.4 (140.1-504.7) 336.6 (193.7-650.7) 0.65 
CD14, ug/mL 2.22 (1.12-6.50) 2.34 (0.89- 10.95) 1.00 
TNFalpha#, pg/mL 1.20 (0.35-15.18) 1.06 (0.17-22.67) 0.59 
Leptin, ng/mL 14.81 (4.63-956.00) 14.79 (5.06-1094.26) 0.10 
Resistin, ng/mL 19.61 (9.76-80.00) 21.08 (9.07-107.69) 0.73 
Adiponectin, ug/mL 2.26 (0.90-8.33) 2.34 (0.62- 15.47) 0.57 
(n=15, *n=7, #n=9) 565 
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Supplementary Fig. S1. Effect of Rifaximin on the genus level composition of 567 
faeces in individual patients. Significant changes, >5%, at the genus level were 568 
plotted for each patient pre (blue bars) and post (orange bars) antibiotic 569 
administration. Significance of genus change was estimated in STAMP using 570 
Fisher’s exact test and multiple testing was controlled for using a Benjamini-571 
Hochberg FDR test. Sample PA07 was not included as changes were <5%. 572 
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